EVALUATION OF THE THERAPEUTIC EQUIVALENCE OF TRAVOPROST PR AND TRAVATAN?. DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN SUBJECTS AFFECTED BY GLAUCOMA OR INTRAOCULAR HYPERTENSION.

PH&T SPA0 个研究点开始时间: 2012年3月2日最近更新: 2013年6月17日

试验速览

暂无简介。

•Adult subjects of either sex,
•Subjects affected by unilateral or bilateral POAG or IOH,
•IOP > 21 mm Hg at Randomization visit,
•Subjects who have given written informed consent, consistent with local requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 71
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 71

•Subjects affected by closed or slit like anterior chamber angle,
•Positive history for acute angle closure,
•Positive history of argon laser trabeculoplasty within 3 months prior screening (the unlasered eye could be enrolled in the study) or of any ocular filtering surgical intervention (the unoperated eye could be enrolled in the study),
•Ocular surgery or ocular inflammation/infection in either eye within 3 months prior to screening,
•Current use of contact lenses,
•Best corrected visual acuity < 20/200,
•Subjects previously treated with Travoprost PR,
•Subjects concomitantly treated with hypotonic agents,
•Known cardiac conduction defects,
•Decompensate heart failure,
•Reactive airway disease,
•Liver impairment with transaminase levels >3x the upper limit of normal range,
•Hypersensitivity to any of the components of the treatment medication,
•Female subjects of child-bearing potential with a positive pregnancy test;
•Female subjects who are nursing;
•Impossibility to attend all the planned visits and/or to have all the tests foreseen by the protocol performed,
•History of non-compliance, alcoholism or drug abuse,
•Subjects having previously participated in this study or in a clinical trial of an investigational drug within the last 30 days prior to the Screening visit,
•Subject has any condition which, in the opinion of the investigator, could interfere with the study results or be considered detrimental to the subject’s welfare.

发起方